Substance use predictors of poor medication adherence: The role of substance use coping among HIV-infected patients in Opioid dependence treatment

AIDS and Behavior

Volumn 17, Issue 1, 2013, Pages 168-173

  Gonzalez, Adam ^a,b   Mimiaga, Matthew J ^a,c   Israel, Jared ^d   Andres Bedoya, C ^a   Safren, Steven A ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c FENWAY INSTITUTE   (United States)

^d UNIVERSITY OF MISSOURI ST LOUIS   (United States)

Author keywords

Cocaine; Coping; HIV AIDS; Medication adherence; Substance use

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADAPTIVE BEHAVIOR; ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG USE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MALE; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS; SUBSTANCE ABUSE; UNITED STATES; VIRUS LOAD;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG USERS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MASSACHUSETTS; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD; YOUNG ADULT;

MLCS; MLOWN;

EID: 84872686222     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0319-6     Document Type: Article

References (48)

1. de Olalla PG, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30:105-10.
2. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-1.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection. J Am Med Assoc. 2010;304:321-33.
5. Kuritzkes DR. HIV drug resistance: new insight and updated practices. Physicians' Res Netw. 2004;9:9-13.
6. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22:75-82.
7. Castilla J, del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101.
8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
9. Quinn TC, Wawer MJ, Sewnkanbo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type-1. N Engl J Med. 2000;342:921-9.
10. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81-8.
11. Gonzalez A, Barinas J, O'Cleirigh C. Substance use: impact on adherence and HIV medication treatment. Curr HIV/AIDS Rep. 2011;8:223-34.
12. Spire B, Lucas GM, Carrier MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262-70.
13. Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: swiss HIV cohort study. J Acquir Immune Defic Syndr. 2010;54:197-203.
14. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195-205.
15. Weber R, Huber M, Rickenbach M, et al. Uptake of and virological response to antiretroviral therapy among HIV-infect former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009;10:407-16.
16. Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23:775-85.
17. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185-94.
18. Abrams DB, Niaura RS. Social learning theory of alcohol use and abuse. In: Blane H, Leonard K, editors. Psychological theories of drinking and alcoholism. New York: Guilford Press; 1987. p. 131-78.
19. Shiffman S, Wills TA. Coping and cessation of substance use. In: Shiffman S, Wills TA, editors. Coping and substance use. New York: Academic Press; 1985. p. 221-40.
20. Gonzalez JS, Batchelder AW, Psaros C, Safren S. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181-7.
21. Waldrop-Valverde D, Valverde E. Homelessness and psychological distress as contributors to antiretroviral adherence in HIV-positive injection drug users. AIDS Patient Care STDs. 2004;19:226-334.
22. Power R, Koopman C, Volk J, et al. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected patients. AIDS Patient Care STDs. 2003;17:245-52.
23. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-77.
24. Liu H, Miller G, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41:315-22.
25. Llabre MM, Weaver KE, Duran RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. AIDS Patient Care STDs. 2006;20:701-11.
26. Safren SA, O'Cleirigh CO, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1-10.
27. Safren SA, O'Cleirigh CM, Bullis JR, Otto MS, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80:404-15.
28. Stirratt MJ, Remien RH, Smith A, et al. The role of HIV serostatus disclosure in antiretroviral medications adherence. AIDS Behav. 2006;10:483-93.
29. Carver CS. You want to measure coping but your protocol is too long: consider the Brief COPE. Int J Behav Med. 1997;4:92-100.
30. Bottonari KA, Safren SA, McQuaid JR, Hsiao C, Roberts JE. A longitudinal investigation of the impact of life stress on HIV treatment adherence. J Behav Med. 2010;33:486-95.
31. Kelly BC, Bimbi DS, Izienicki H, Parsons JT. Stress and coping among HIV-positive barebackers. AIDS Behav. 2009;13:792-7.
32. Gay C, Portillo CJ, Kelly R, et al. Self-reported medication adherence and symptom experience in adults with HIV. J Assoc Nurses AIDS Care. 2011;22:257-68.
33. Hinkin CH, Hardy DJ, Mason KL, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:S19-25.
34. Puskas CM, Forrest JI, Parashar S, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep. 2011;8:277-87.
35. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18:248-57.
36. Baron R, Kenny D. The moderator-mediator distinction in social psychological research: conceptual strategic and statistical considerations. J Pers Soc Psychol. 1986;51:1173-82.
37. Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. In: Leinhardt S, editor. Sociological Methodology. Washington: American Sociological Association; 1982. p. 290-312.
38. Hessol NA, Weber KM, Holman S, et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health. 2009;18:1627-37.
39. Gonzalez A, Vujanovic AA, Johnson KA, Leyro TM, Zvolensky MJ. The role of mindful attention in regard to the relation between negative affect reduction outcome expectancies and emotional vulnerability among adult daily smokers. Cogn Ther Res. 2009;33:645-56.
40. Johnson KA, Zvolensky MJ, Marshall EC, Gonzalez A, Abrams K, Vujanovic AA. Linkages between cigarette smoking outcome expectancies and negative emotional vulnerability. Addict Behav. 2008;33:1416-24.
41. Blashill AJ, Perry N, Safren SS. Mental health: a focus on stress, coping, and mental illness as it related to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep. 2011;8:215-22.
42. Stone AA, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med. 1994;16:99-202.
43. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21:4-9.
44. Palepu A, Milloy M, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected drug users. J Urban Health. 2011;88:545-55.
45. Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and antiretroviral treatment among HIV-infected Black women. J Community Health. 2004;29:117-27.
46. Baum M, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93-9.
47. Duncan R, Shapshak P, Page JB, et al. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV-infected African American women. Front Biosci. 2007;12:1488-95.
48. McLellan TA, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis. 1980;168:26-33.